Related Experiment Video

Updated: May 20, 2026

Sample Preparation to Bioinformatics Analysis of DNA Methylation: Association Strategy for Obesity and Related Trait Studies
14:56

Sample Preparation to Bioinformatics Analysis of DNA Methylation: Association Strategy for Obesity and Related Trait Studies

Published on: May 6, 2022

Association of adiponectin gene G276T polymorphism with atherogenic indicators in obese children

Beata Pyrzak1, Malgorzata Ruminska, Aneta Czerwonogrodzka-Senczyna

  • 1Department of Pediatric and Endocrinology, Warsaw Medical University, Warsaw, Poland. beata.pyrzak@wum.edu.pl

Advances in Experimental Medicine and Biology
|July 28, 2012
PubMed

Insights

The adiponectin G276T gene polymorphism is linked to lower adiponectin levels in obese children. This genetic variation did not significantly associate with atherosclerosis markers like carotid intima-media thickness in the study population.

Area of Science:

  • Medical Genetics
  • Pediatric Endocrinology
  • Cardiovascular Research

Background:

  • Adiponectin is crucial for preventing atherosclerosis.
  • The adiponectin G276T gene polymorphism influences adiponectin levels and metabolic health.
  • Obesity in children is a growing concern linked to cardiovascular risk.

Purpose of the Study:

  • To examine the relationship between the adiponectin G276T gene polymorphism and atherosclerosis indicators in obese children.
  • To assess how this genetic variation affects anthropometric measures, lipid profiles, and inflammatory markers.

Main Methods:

  • Study included 159 children (125 obese, 34 non-obese).
  • Adiponectin G276T polymorphism identified via PCR-RFLP.
  • Measured anthropometrics, lipids (TC, HDL, LDL, TG), C-reactive protein (CRP), adiponectin, and performed OGTT. Carotid intima-media thickness (IMT) assessed in 82 children.

Main Results:

  • Obese children exhibited higher atherogenic risk factors than non-obese children, correlating with CRP and lipids.
  • Elevated IMT was observed in 91% of obese children, linked to CRP.
  • Children with the GG genotype had lower BMI, TC, TG, and higher adiponectin levels compared to TT homozygotes; however, other markers did not differ significantly.

Conclusions:

  • Adiponectin levels are decreased in obese children with the G276T polymorphism in the adiponectin gene.
  • The study did not find significant associations between the adiponectin G276T polymorphism and carotid IMT, lipid profiles, blood pressure, or HOMA-IR in obese children.

More Related Videos

Mechanism of Regulation of Adipocyte Numbers in Adult Organisms Through Differentiation and Apoptosis Homeostasis08:34

Mechanism of Regulation of Adipocyte Numbers in Adult Organisms Through Differentiation and Apoptosis Homeostasis

Published on: June 3, 2016

Characterization of Adipocyte-Derived Extracellular Vesicle Secretion Using a CD63-GFP Reporter Mouse Model In Vivo and In Vitro10:40

Characterization of Adipocyte-Derived Extracellular Vesicle Secretion Using a CD63-GFP Reporter Mouse Model In Vivo and In Vitro

Published on: December 5, 2025

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...